Copyright: ©Author(s) 2026.
World J Nephrol. Jun 25, 2026; 15(2): 118160
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118160
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118160
Table 2 Comparison of outcomes
| Outcome | Incidence rate (Total cohort) | Incidence rate (NELL1-MN) | Incidence rate (PLA2R-MN) | P value |
| Remission (Complete or partial) | 7.2/100-pt-months | 11.7/100-pt-months | 5/100-pt-months | 0.01 |
| Complete remission | 5.9/100-pt-months | 10.3/100-pt-months | 3.8/100-pt-months | 0.01 |
| Partial remission | 1.3/100-pt-months | 1.3/100-pt-months | 1.2/100-pt-months | 0.89 |
| No remission | 1.7/100-pt-months | 0/100-pt-months | 2.5/100-pt-months | 0.04 |
| Spontaneous remission | 1.3/100-pt-months | 3.4/100-pt-months | 0.3/100-pt-months | 0.01 |
- Citation: Sathiavageesan S, Krishnan A, Sampathkumar K, Muthu R. Multicentre comparative study of neural epidermal growth factor-like 1 protein vs M-type phospholipase A2 receptor-associated membranous nephropathy. World J Nephrol 2026; 15(2): 118160
- URL: https://www.wjgnet.com/2220-6124/full/v15/i2/118160.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i2.118160